Abstract
In this study, we used RNA sequencing (RNA-seq) to analyze and compare bulk cell samples from wild-type (WT) dermal mesenchymal stem cells (DMSCs) (n = 3) and Prx II knockout DMSCs (n = 3). The purpose of the study was to elucidate the role of Prx II on allogeneic immune rejection of transplanted DMSCs. The results revealed differential expression of 472 genes (176 up-regulated and 296 down-regulated; p ≤ 0.05) between the PrxII+/+ (WT) and PrxII−/− sample groups. When highly regulated genes were categorized according to the Gene Ontology (GO) molecular function classification and the Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis, the PrxII−/− samples showed a robust downward trend in allograft rejection. The study identified 43 all immunologically rejected differentially expressed genes, of which 41 showed lower expression in the PrxII−/− vs. PrxII+/+ (WT) samples. These findings suggest that Prx II gene knockout may down-regulate the allograft rejection that occurs during DMSCs transplantation and improve the survival rate of DMSCs in the host. This study provides a new perspective on the clinical treatment of stem cell transplantation.
Highlights
Mesenchymal stem cells (MSCs) are pluripotent stem cells that exist in many tissues and can differentiate into several cell types [1, 2]
Compared to the WT, the expression of most of these cytokines and chemokines was down-regulated in the Homo samples. These results suggest that reducing Prx II expression may be an effective way to reduce dermal mesenchymal stem cells (DMSCs) rejection
Sample correlation analysis and principal component analysis To determine whether the gene expression profiles presented different correlations between the two sample groups, we analyzed the RNA sequencing (RNA-seq) data of the WT and Homo samples using the Pearson correlation coefficient (Fig. 2a)
Summary
Mesenchymal stem cells (MSCs) are pluripotent stem cells that exist in many tissues and can differentiate into several cell types [1, 2]. They are widely used in transplantation and tissue regeneration. Transplantation rejection is still an inevitable problem in the practical application of allogeneic mesenchymal stem cells and their derivatives. The major cause of immune rejection is the activation of T lymphocytes by the major histocompatibility complex (MHC), which results in a specific immune response. Strategies to reduce organ rejection and improve the survival rate after transplantation will be crucial in the development of transplantation medicine
Sign-in/Register to view highlights & summary 
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call